BiotechTube

Upadacitinib + Dupilumab + Placebo to dupilumab + Placebo to upadacitinib

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atopic Dermatitis

Conditions

Atopic Dermatitis

Trial Timeline

Feb 21, 2019 → Dec 9, 2020

NCT ID
NCT03738397

About Upadacitinib + Dupilumab + Placebo to dupilumab + Placebo to upadacitinib

Upadacitinib + Dupilumab + Placebo to dupilumab + Placebo to upadacitinib is a phase 3 stage product being developed by AbbVie for Atopic Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03738397. Target conditions include Atopic Dermatitis.

What happened to similar drugs?

20 of 20 similar drugs in Atopic Dermatitis were approved

Approved (20) Terminated (1) Active (0)
✅LebrikizumabEli LillyApproved
✅tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
✅tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
✅tacrolimusAstellas PharmaApproved
✅tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
✅Tacrolimus 0.03% + Fluticasone 0.005%Astellas PharmaApproved
✅Protopic + Corticosteroid + placeboAstellas PharmaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03738397Phase 3Completed

Competing Products

20 competing products in Atopic Dermatitis

See all competitors
ProductCompanyStageHype Score
LebrikizumabEli LillyPhase 3
40
Baricitinib + Placebo + Topical corticosteroidEli LillyPhase 3
40
LebrikizumabEli LillyApproved
50
LebrikizumabEli LillyPhase 3
40
Lebrikizumab + PlaceboEli LillyPhase 3
44
BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + GentamicinHoth TherapeuticsPhase 1
19
LebrikizumabEli LillyPhase 3
40
ASN008Formation BioPhase 2
25
ENS-002Concerto BiosciencesPhase 1
11
nemolizumab (CIM331)Chugai PharmaceuticalPhase 2
35
YH35324 + Placebo + OmalizumabYuhanPhase 1
29
YH35324 + Placebo + OmalizumabYuhanPhase 1
29
DS-2741a + PlaceboDaiichi SankyoPhase 1
21
SUN13834 + PlaceboDaiichi SankyoPhase 2
35
5 mg ASB17061 + Placebo + 10 mg ASB17061 + 20 mg ASB17061Daiichi SankyoPhase 2
35
Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%Astellas PharmaPhase 2
35
tacrolimus ointmentAstellas PharmaPhase 3
40
tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
43
tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
43
tacrolimus ointment 0.03% + hydrocortisone acetate ointment 1% + hydrocortisone butyrate ointment 0.1% + Meningitec + AC VAXAstellas PharmaPhase 2
35